Trials
3 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SYH2070 injection, 150 mg, 300 mg, 400 mg, SC, administration duration: 24 weeks”In the company’s words, NCT07695597 on ClinicalTrials.gov
- Tested for
- Mixed Hyperlipidemia, Diagnosed With HoFH
- Main trialPhase 2
- “This is a randomized, double-blind, placebo-parallel, multicenter phase II clinical trial to evaluate the efficacy and safety of SYH2070 injection in participants with mixed hyperlipidemia.”In the company’s words, NCT07695597 on ClinicalTrials.gov
Other drugs for Mixed Hyperlipidemia
Coming up2
- 30 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- 16 Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Apr 2027 | A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia | |
| Phase 2Recruiting | 16 Sep 2027 | Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia | |
| Phase 1Recruiting | 1 Nov 2026 | A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026